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Abstract
Background: Oocyte cryopreservation is an important method used in a number of human fertility circumstances.
Here, we compared the survival, in vitro maturation, fertilization, and early embryonic development rates of frozen-
thawed human immature oocytes using two different cryopreservation methods.
Methods: A total of 454 failed-matured oocytes [germinal vesicle (GV) and metaphase I (MI) stages] were collected
from 135 patients (mean age 33.84 +/- 5.0 y) who underwent intracytoplasmic sperm injection (ICSI) cycles between
February 2009 and December 2009 and randomly divided into a slow freezing group [1.5 mol/L-1, 2-propanediol
(PROH) + 0.2 mol/l sucrose] and vitrification group [20% PROH + 20% ethylene glycol (EG) + 0.5 mol/l sucrose].
Results: The vitrification protocol yielded a better survival rate than the slow freezing protocol at each maturation
stage assessed. Regardless of the maturation stage (GV + MI), the slow freezing protocol had a significantly lower
survival rate than the vitrification protocol (p < 0.001). In addition, a significant difference was found in the survival
rates between GV and MI oocytes regardless of the protocol used (90.1 vs. 64.7%, respectively; p < 0.01). We also
found that the maturation rates of GV and MI oocytes from the slow freezing and vitrification groups were 16.7 vs.
24.4% and 50.8 vs. 55.4%, respectively. Regardless of the protocol used, the GV oocytes had significantly lower
viability than MI oocytes after 36 h of in vitro maturation (21.2 vs. 54.0%, respectively; p < 0.01). In addition, the GV
and MI oocytes from the slow freezing group had a markedly lower maturation rate than those from the vitrification
group (33.6 vs. 43.1%, respectively), but no statistical difference was found between the two groups (P > 0.05). For
the GV-matured oocytes, no fertilized eggs were obtained in the slow-freezing group, while a 19.0% (4/21)
fertilization rate was observed in the vitrification group. For the MI-matured oocytes, fertilization rates for the slow
freezing and vitrified groups were 36% and 61.1%, respectively, but no significant difference was found between the
two groups (PIn the Methods section in the MS, all procedures were compliant with ethical guidelines, i.e. approved
by the Ethical Committee of our university and Informed Consent signed by each patient. > 0.05). In the GV
vitrification group, no embryo formed; however, in the MI slow freezing group, 12 oocytes were fertilized, but only
two achieved cleavage and were subsequently blocked at the 2-cell stage. In the MI vitrification group, a total of 22
embryos were obtained, five of which developed to the blastocyst stage.
Conclusions: Vitrification is superior to the slow freezing method in terms of the survival and developmental rates
for the cryopreservation of human failed-matured oocytes. In addition, GV oocytes appeared to be more resistant
than MI oocytes to the low temperature and cryoprotectant used during cryopreservation.
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maturation rate, fertilization, development rates
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Oocyte cryopreservation is an important method used to
preserve female fertility under different pathological condi-
tions [1] and avoids ethical issues that are associated with
embryo cryopreservation. This method provides the safe
storage of excess oocytes during assisted reproductive
technology (ART) therapies and improves the establish-
ment of oocyte banks. Oocyte preservation can also pro-
vide a solution for cancer patients wishing to preserve
fertility before undergoing chemotherapy or radiation
therapy, or for young cancer patients who do not as yet
have a male partner [2]. When the risk and delay of stimu-
lation are unacceptable for patients, the cryopreservation
of immature oocytes followed by in vitro maturation
(IVM) can solve this problem [3]. The main problem asso-
ciated with cryopreservation of metaphase II oocytes
(mature oocytes) is the sensitivity of microtubule spindles
to low temperatures and cryoprotectants [4]; however, this
can be avoided by cryopreserving immature oocytes,
which have chromosomes within the nuclear membrane
that are not yet arranged on the microtubule spindles [5].
The location of the chromosomes in immature oocytes is
thought to provide protection from the direct exposure to
low temperature and cryoprotectants during freezing and
thawing [5]. Cryopreservation of immature oocytes is a
method for circumventing spindle damage, but the main
disadvantage of cryopreservation of immature oocytes is
the fact that IVM is required after thawing. Although IVM
is routine in some animal species, it is not easily per-
formed with human oocytes, and very few successful preg-
nancies from cryopreserved immature oocytes have been
reported [6,7].
There are two major techniques for oocyte cryopreser-
vation: slow freezing and vitrification. To date, no univer-
s a ls l o wf r e e z i n gp r o t o c o le x i sts. Computer-controlled
automatic freezing devices are often used for slow freez-
ing. In general, the standard slow freezing protocol con-
sists of two stages: freezing and thawing. The vitrification
process brings the samples to an extremely low tempera-
ture in a glassy state in order to avoid the formation of
ice crystals. This is achieved by combining the use of a
high concentration of cryoprotective solution with an
extremely rapid cooling speed. Vitrification has the
advantage of being carried out rapidly and easily and
does not require expensive equipment. However, it can
also easily expose samples to osmotic shock and toxicity
due to the high concentration of cryoprotectant used,
which may affect the viability of the embryo/oocyte. The
common vitrification protocol for embryo/oocyte cryo-
preservation also has two stages: cooling and warming.
The majority of studies have shown that vitrification
methods are more efficient and reliable than any version
of the slow freezing method [8-10].
In the present study, the cryopreservation of failed-
matured oocytes collected from intracytoplasmic sperm
injection (ICSI) therapy cycles was performed in order to
explore cryopreservation of human immature oocytes. In
addition, we aimed to develop a new option for the cryo-
preservation of human oocytes and provide a better
method for preserving fertility.
Methods
Study period and patients
A total of 454 failed-matured oocytes obtained from 135
patients (mean age 33.56 +/- 4.0 y) who underwent ICSI
cycles between February 2009 and December 2009 were
used for this study. ICSI treatment was performed due to
male infertility, oligozoospermia, and obstructive azoos-
permia. The study was initially approved by the ethical
and scientific committee of the first affiliated hospital of
Anhui Medical University, China. Patients included in
the study were thoroughly informed and signed written
consent forms. All procedures in the Methods section
were compliant with ethical guidelines, i.e. approved by
the Ethical Committee and Informed Consent signed by
each patient.
Stimulation protocol and oocyte recovery procedures
The patients were given standard ovarian stimulation
using a long or short protocol. After down-regulation
with a gonadotropin-releasing hormone antagonist
(Dipherline, IPSEN, France), the patients were stimulated
with human menopausal gonadotropin (r-FSH, Serono,
Switzerland; HMG, Lizhu, China). The oocyte retrieval
was performed through vaginal puncture under ultra-
sound guidance. After ovum pick-up, oocytes were enzy-
matically denuded of cumulus cells with 60-80 mU/ml
Hyaluronidase solution (Sigma, USA) in order to assess
nuclear maturity. All retrieved metaphase II (MII)
oocytes were used for patients’ treatments, and the germ-
inal vesicle (GV) and metaphase I (MI) oocytes, which
are also called failed-matured oocytes, were divided into
either the slow freezing or vitrification groups through a
random computer-generated list. Prior to cryopreserva-
tion, the oocytes were evaluated microscopically based
on morphology to identify high-quality oocytes with an
appropriate size, normal zona pellucida, and integral
membrane.
Protocols for oocytes slow freezing
To freeze, the failed-matured oocytes were first placed
in equilibration solution, which was composed of
HTF1023 (SAGE, USA), 15% serum protein substitute
(SPS, SAGE, USA), and 1.5 mol/L-1.2-propanediol
(PROH, Sigma, USA) for 10 min at room temperature
(RT), and then placed in freezing solution at RT for
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Page 2 of 61 min, which was composed of HTF1023 with 15% SPS,
1.5 mol/L-PROH, and 0.2 mol/l sucrose. Subsequently, a
small amount of the freezing solution containing oocytes
was loaded into 0.25 ml plastic straws (MINITüB,
Japan). The plastic straws were then transferred into an
automated freezing machine (CL-8800, Australia) with
an initial chamber temperature of 21°C. The tempera-
ture was reduced to -7°C at a rate of -2°C/min and ice
seeding was induced manually. After a holding time of
10 min at -7.0°C, the straw was slowly cooled to -35°C
at a rate of -0.3°C/min and then rapidly cooled to -80°C
at a rate of -45°C/min. After 15 min at the stabilization
temperature, the straws were immediately placed into
liquid nitrogen for a minimum of one month of storage.
To thaw the samples, the plastic straws were first air-
warmed for 40 s and then immersed in a 31°C water bath
for 60 s for complete removal of all ice.The cryoprotec-
tants were removed at RT in the following solutions:
HTF1023 with 15% SPS and 0.5 mol/l sucrose (37°C,
10 min), HTF1023 with 15% SPS and 0.3 mol/l sucrose
(37°C, 10 min), and HTF1023 with 15% SPS (37°C,
7 min).
Protocol for oocytes vitrification
The oocytes were vitrified in equilibration medium
[HTF1023, 30% SPS, 7.5% (v/v) PROH, and 7.5% (v/v)
EG] at RT for 5-9 min, followed by incubation in vitrifi-
cation medium [HTF1023, 30% SPS, 0.5 M sucrose, 15%
(v/v) PROH, and 15% (v/v) EG] at RT for 30 s. The
samples were then loaded into cryotops (KITAZATO
Biopharma, Japan) at a volume less than 1 μl and imme-
diately submerged into liquid nitrogen for at least 1
month of storage.
To thaw the vitrified oocytes, the cryotops were taken
out of the liquid nitrogen and gradually warmed to RT in
the following solutions: Thawing Medium: HTF1023 +
30% SPS + 1.0 M Sucrose (37°C, 1 min); Diluent Medium
I: HTF1023 + 30% SPS + 0.5 M Sucrose (37°C, 3 min);
Diluent Medium II: HTF1023 +30% SPS + 0.25 M Sucrose
(37°C, 3 min); Washing Medium I: HTF1023 + 30% SPS
(37°C, 3 min); and Washing Medium II: HTF1023 + 30%
SPS (37°C, 3 min)
After thawing, all of the oocytes were cultured in fertili-
zation medium (Cook, USA) at 37°C, 6% CO2, and 5% O2
and checked after 1 h for survival based on the membrane
integrity. If the rim of the cytoplasmic periphery appeared
as a smooth arc under an inverted microscope, it indicated
that the oocyte was viable; if the rim was irregular and the
cytoplasm was diffuse, then the oocyte was not viable.
Protocol for IVM, ICSI, and embryo culture
The frozen-thawed immature oocytes were cultured in self-
prepared IVM medium supplemented with 75 mUI/ml of
FSH (Gonal-F, Serono, Swiss), 75 mIU/mlhCG (Profasi,
Serono, Swiss) and 20% patient serum [11] in a humidified
atmosphere at 6% CO2 and 5% O2 at 37°C. The appearance
of the first polar body (PB1) indicated oocyte maturation
during culture. The GV and MI oocytes were cultured for
24 h and the mature oocytes with PB1 were isolated and
inseminated by ICSI using sperm donors who had signed
informed consent forms. The remaining oocytes were
placed back into culture for up to an additional 12 h, and
oocyte maturation was observed every hour during the
incubation period.
The in vitro matured oocytes were inseminated by
ICSI using sperm donors. Injected oocytes were indivi-
dually cultured in micro-drops containing cleavage med-
i u m( C o o k ,U S A )a t3 7 ° C ,6 %C O 2,a n d5 %O 2.
Fertilization was assessed 16-18 h after the injection for
the appearance of two pronuclei and two polar bodies.
The formed embryos were cultured for 2-3 d in the
cleavage medium and the embryonic development was
evaluated daily by scoring fragmentation as well as the
number and appearance of blastomers.
Data were compared using c
2 tests. Yates corrected p
values less than 0.05 were regarded as statistically
significant.
Results
Freezing and thawing: survival rates
A total of 454 failed-matured oocytes were randomized
into two different groups. The survival rates of oocytes
from the two freezing groups at different developmental
stages are shown in Table 1. Regardless of the maturation
stage (VG + MI), the slow freezing method induced a sig-
nificantly lower survival rate of 62% (119/192) compared
to 82% (216/262) for the vitrification method (p < 0.01).
Survival rates of the GV oocytes were 85.7% (60/70) for
the slow-freezing and 93.5% (86/92) for the vitrification
methods, and survival rates of the MI oocytes were 48.4%
(59/122) and 76.5% (130/170) for the slow freezing and
vitrification methods, respectively. Regardless of the proto-
col used, a significant difference was found in the viability
between the GV and MI oocytes (90.1 vs. 64.7%,
Table 1 Comparison of the survival rates between the
slow-freezing and vitrification groups
Slow-freezing Vitrification Total
GV + MI collected 192 262 454
GV collected 70 92 162
MI collected 122 170 292
GV + MI survival (%) 119 (62.0) 216 (82.4) * 335 (73.8)
GV survival (%) 60 (85.7) 86 (93.5) 146 (90.1)
MI survival (%) 59 (48.4) 130 (76.5) * 189 (64.7) **
*Significantly different between the slow-freezing and vitrification groups
(P < 0.01)
**Significantly different between the number of GV and MI that survived
(P < 0.01)
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oocytes were more resistant to the freeze/thaw procedure
than the MI oocytes. In addition, the vitrification protocol
provided a better survival rate than the slow-freezing
protocol.
In vitro maturation rates
As shown in Table 2, the maturation rate of the GV
oocytes was 16.7% (10/60) under the slow freezing process
and 24.4% (21/86) under the vitrification process. In addi-
tion, the maturation rates for the MI oocytes were 50.8%
(30/59) for the slow freezing process and 55.4% (72/130)
for the vitrification process. Regardless of the protocol
used, the GV oocytes had significantly worse viability after
24-36 h of IVM than the MI oocytes (21.2 vs. 54.0%,
respectively; p < 0.01). Regardless of the maturation stage,
the oocytes from the slow freezing process had a markedly
lower maturation rate than those from the vitrification pro-
cess (33.6 vs. 43.1%, respectively); however, no statistical
difference was found between the two groups (p > 0.05).
Fertilization and development
All of the in vitro matured oocytes were inseminated by
ICSI using donated semen and fertilization was assessed
16-18 h after the injection for the appearance of two pro-
nuclear and two polar bodies (Table 2). For the GV-
matured oocytes, no fertilized eggs formed from the slow
freezing group, while a 19.0% (4/21) fertilization rate was
achieved in the vitrification group. For the MI-matured
oocytes, fertilization rates were 36.0% (12/30) and 61.1%
(44/72) for the slow freezing and vitrification groups,
respectively, without a significant difference between the
two groups (p > 0.05). Regardless of the protocol used, the
MI oocytes had a significantly higher fertilization rate than
the GV oocytes (58.8 vs. 12.9%, respectively; p < 0.01) fol-
lowing cryopreservation, IVM, and insemination.
In the GV vitrification group, no embryo formed. In
addition, of the 12 fertilized oocytes in the slow freezing
MI group, only two oocytes achieved cleavage, which
were subsequently blocked at the 2-cell stage. In the MI
vitrification group, a total of 22 embryos formed, and of
them, five embryos developed to the blastocyst stage.
Importantly, there was a significant difference in the
cleavage rates between the two groups (50.0 vs. 16.7%,
respectively; p < 0.05).
Discussion
In routine IVF or ICSI cycles, some immature oocytes,
called failed-matured oocytes, are often observed during
oocyte retrieval. These oocytes are generally considered
u n u s a b l es i n c et h e yh a v eal o wp o t e n t i a lt od e v e l o pi n t o
an embryo. In 2004, Chian et al. [12] reported pregnan-
cies and live births as a result of IVF with oocytes
retrieved during the natural cycle and subjected to IVM.
Based on these important findings, we hypothesized that
some of the failed-matured oocytes may be competent
for the full-term development of a fetus after IVM, fertili-
zation, and in vitro culture. Therefore, these failed-
matured oocytes may provide a benefit for patients,
oocyte donation, and the study of the cryopreservation of
human immature oocytes.
The cryopreservation of human immature oocytes has
distinct advantages compared to mature oocytes. Imma-
ture oocytes may circumvent the problem of spindle
damage that frequently occurs in mature oocytes during
cryopreservation, since the chromosomes remain within
the nucleus [5]. This unique position protects them from
direct exposure to low temperatures and cryoprotectants
[4]. Moreover, the cryopreservation of immature oocytes
could allow cancer patients to preserve fertility before
receiving chemotherapy or radiation therapy without
delaying treatment or experiencing other risks due to
oocytes induction [3]. However, the cryopreservation of
human immature oocytes also has disadvantages, and fro-
zen and thawed immature oocytes from IVM followed by
insemination have been shown to have lower fertilization
and cleavage rates than mature oocytes. To date, very few
human live births have been reported following the
Table 2 Status on maturation, fertilization and development of failed-matured oocytes that survived cryopreservation
Viable GV Oocytes Viable MI Oocytes
Slow-freezing Vitrification Slow-freezing Vitrification
No. of oocytes matured in vitro (%) 31 (21.2) total 102 (54.0)* total
10 (16.7) 21 (24.4) 30 (50.8) 72 (55.4)
No. of fertilized (%) 4 (12.9) total 60 (58.8)* total
0 (0.0) 4 (19.0) 12 (36.0) 44 (61.1)
No. of cleaved (%) 0 (0.0) total 24 (40.0) total
0 (0.0) 0 (0.0) 2 (16.7) 22 (50.0)**
No. of blastocysts formed (%) 0 (0.0) total 5 (20.8) total
0 (0.0) 0 (0.0) 0 (0.0) 5 (22.7)
*Significantly different between the GV and MI oocytes that survived (P < 0.01)
** Significantly different between the slow-freezing and vitrification groups (P < 0.05)
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Therefore, the cryopreservation of mature oocytes is still
a more efficient method than the cryopreservation of
immature oocytes [16-18]. For substantial progress to be
made in the cryopreservation of human immature
oocytes, more effort and creativity should be placed on
studies that explore these methods.
In the process of performing ICSI, failed-matured
oocytes are often observed and easily collected. In addi-
tion, some failed-mailed oocytes have been reported to
have the potential to develop healthy offspring [12].
Based on these findings, we used failed-matured oocytes
to study cryopreservation methods of human immture
oocytes. The extent of cell injury in the failed-matured
oocytes at each different stage was evaluated in detail fol-
lowing the freeze/thaw process after slow freezing or
vitrification protocols were performed.
In this study, we found a significant difference in the via-
bility of oocytes between the vitrification and slow freezing
protocols regardless of the maturation stage. These find-
ings support the hypothesis that vitrification provides bet-
ter viability of failed-matured oocytes than the slow
freezing technique. Importantly, five blastocysts were
obtained from the vitrification group, whereas no blasto-
cyst formed from the slow-freezing group. Although the
IVM rate in our study was not significantly different
between the two groups, the vitrification procedure still
achieved better results. Therefore, these results demon-
strate that the vitrification process is superior to the slow
freezing method used for cryopreservation of human
failed-matured oocytes. According to our fertilization and
developmental results, we hypothesize that vitrification
provides better preservation of microtubule organization
and a reduction of cytoskeletal spindle damage compared
to the slow freezing method.
In the present study, we found that GV oocytes had a
significantly higher viability than MI oocytes regardless
of the protocol used. These results suggest that GV
oocytes are more resistant to the freeze/thaw procedure
than MI oocytes, which may be related to the unique cel-
lular structure present at the GV stage. GV oocytes have
large germinal vesicles and two large cell membranes: a
cytoplasmic membrane and GV membrane. During the
freeze/thaw process, the two membranes of GV oocytes
m a yb em o r er e s i s t a n tt oo s m o t i cp r e s s u r ec h a n g e sa n d
therefore avoid the disintegration of the cytoplasmic
membrane, which can occur in MI oocytes.
In conclusion, the study presented here has demon-
strated that vitrification is superior to the slow freezing
method in terms of survival and developmental rates of
human failed-matured oocytes that have been cryopre-
served. In addition, GV oocytes appeared to be more resis-
tant to the low temperature and cryoprotectant than the
MI oocytes during the cryopreservation process. Since
discarded oocytes were used for this study, additional stu-
dies are needed with a larger sample number in order to
definitively explore the use of human failed-matured
oocytes in cryopreservation for human fertility.
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